Predictive Factors For Thrombopoietin Receptor Agonist Free Responses In Chronic Itp Patients: A Multicenter Retrospective Study With Long-Term Follow-Up

Background. In clinical practice, tapering off thrombopoietin receptor agonists (TPO-RA) in immune thrombocytopenia (ITP) is considered if therapy is no longer needed due to a decrease in the disease activity favoring sustained treatment-free responses (TFR). To date, there are no predictors to identify when this approach is likely to be successful, other than earlier start of TPO-RA, and robust platelet responses.